Antengene Corporation Limited
Research Antengene Corporation Limited (6996.HK) on Bullrun: market cap HKD 1.89B, P/E 34.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6996.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.89B
- P/E34.2
- Financial periodFY2025
- RevenueCNY 105.34M
- Revenue growth14.6%
- Net income-CNY 239.13M
- Free cash flow-CNY 178.86M
- Gross margin83.6%
Valuation Snapshot
latest market cap is HKD 1.89B; P/E is 34.2.
Peer valuation comparison
Latest P/E is 34.22x versus a Healthcare sector median of 21.69x (57.8% above).
Latest P/E is 34.22x versus a China median of 16.26x (110.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 105.34M | -CNY 239.13M | -CNY 178.86M | 83.6% | -0.38 | CNY 718.25M | CNY 257.51M | CNY 642.43M |
| FY2024 | CNY 91.95M | -CNY 319.25M | -CNY 382.58M | 81.9% | -0.51 | CNY 884.54M | CNY 249.44M | CNY 850.80M |
| FY2023 | CNY 67.31M | -CNY 581.18M | -CNY 778.87M | 81.7% | -0.94 | CNY 1.18B | CNY 201.02M | CNY 1.15B |
| FY2022 | CNY 160.14M | -CNY 601.49M | -CNY 671.56M | 82.4% | -0.97 | CNY 1.78B | CNY 57.96M | CNY 1.71B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.89B | 34.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Antengene Corporation Limited
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Antengene Corporation Limited's market cap?
Antengene Corporation Limited's market capitalization is HKD 1.89B.
What is Antengene Corporation Limited's P/E ratio?
Antengene Corporation Limited's price-to-earnings (P/E) ratio is 34.2.
What does Antengene Corporation Limited do?
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients.